PureTech

PureTech-Founded Celea Therapeutics Raises $180 Million to Accelerate Deupirfenidone Development for IPF

PureTech Founded Entity Celea Therapeutics Completes $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF) PureTech Health plc a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation…

Read MorePureTech-Founded Celea Therapeutics Raises $180 Million to Accelerate Deupirfenidone Development for IPF
AGC Pharma Chemicals Validates Facilities for CDMO Services via Scientist.com’s VERIF.i® Program

AGC Pharma Chemicals Validates CDMO Facilities Through Scientist.com’s VERIF.i® Program

AGC Pharma Chemicals Validates Facilities for CDMO Services via Scientist.com’s VERIF.i® Program Scientist.com, the life sciences industry’s leading AI-enabled R&D orchestration platform and digital marketplace, and AGC Pharma Chemicals, a leading global Contract Development and Manufacturing Organization (CDMO) for small molecule…

Read MoreAGC Pharma Chemicals Validates CDMO Facilities Through Scientist.com’s VERIF.i® Program
Rezon Bio Appoints Dr. Hubert Scholze as Chief Business Officer to Drive Global Commercial Growth

Rezon Bio Appoints Dr. Hubert Scholze as Chief Business Officer to Drive Global Commercial Growth

Rezon Bio Appoints Dr. Hubert Scholze as Chief Business Officer to Accelerate Global Commercial Expansion Rezon Bio, a science-driven European biologics contract development and manufacturing organization (CDMO), announced the appointment of Dr. Hubert Scholze as Chief Business Officer (CBO), effective…

Read MoreRezon Bio Appoints Dr. Hubert Scholze as Chief Business Officer to Drive Global Commercial Growth
Bureau

Bureau Veritas Agrees to Sell Oil, Petrochemicals, and Coal Testing & Inspection Business Under LEAP | 28 Portfolio Rotation Strategy

In Line With the LEAP | 28 Portfolio Rotation Strategy, Bureau Veritas Signs an Agreement to Sell Its Oil & Petrochemicals and Coal Testing and Inspection Business Bureau Veritas, a global leader in Testing, Inspection, and Certification services (TIC), announces…

Read MoreBureau Veritas Agrees to Sell Oil, Petrochemicals, and Coal Testing & Inspection Business Under LEAP | 28 Portfolio Rotation Strategy
ZEISS-Meditec-Chooses-Nirrin-Technologies

ZEISS Meditec Chooses Nirrin Technologies’ Atlas® System to Modernize Hyaluronic Acid Manufacturing

ZEISS Meditec Selects Atlas® System from Nirrin Technologies to Modernize Hyaluronic Acid Manufacturing Workflows Nirrin Technologies, a developer of analytical tools designed to transform bioprocess analytics, announced that Hyaltech, a Carl ZEISS Meditec (CZM) company has purchased an Atlas® system to support…

Read MoreZEISS Meditec Chooses Nirrin Technologies’ Atlas® System to Modernize Hyaluronic Acid Manufacturing
Merck Agrees to Acquire Bio-Techne, Strengthening Leadership Position in Fast-Growing Life Sciences Markets

Merck to Acquire Bio-Techne, Expanding Leadership in High-Growth Life Sciences Markets

Merck Agrees to Acquire Bio-Techne, Strengthening Leadership Position in Fast-Growing Life Sciences Markets Merck, a leading science and technology company, and Bio-Techne Corporation, a Minneapolis-based global provider of life science tools, analytical technologies, and consumables, today entered into a definitive…

Read MoreMerck to Acquire Bio-Techne, Expanding Leadership in High-Growth Life Sciences Markets
Antares Therapeutics

Antares Therapeutics Partners with Novartis to Discover, Develop, and Commercialize First-in-Class Cancer Therapies

Antares Therapeutics Enters Agreement with Novartis to Discover, Develop and Commercialize First-in-Class Cancer Therapies Antares Therapeutics, Inc. a biotechnology company developing first-in-class precision medicines for cancer and other serious diseases, today announced a strategic collaboration with Novartis to discover, develop…

Read MoreAntares Therapeutics Partners with Novartis to Discover, Develop, and Commercialize First-in-Class Cancer Therapies
Verici

Verici Dx Receives New York State Approval, Expanding Nationwide Access to the Tutivia™ Kidney Transplant Rejection Test

Verici Dx Receives New York State Approval, Establishing Nationwide Access to Tutivia™ Kidney Transplant Rejection Test Verici Dx plc  a developer of advanced clinical diagnostics for organ transplant, announced it has received clinical laboratory accreditation from the New York State…

Read MoreVerici Dx Receives New York State Approval, Expanding Nationwide Access to the Tutivia™ Kidney Transplant Rejection Test
Definium Therapeutics

Definium Therapeutics Reports Positive Phase 3 Results for DT120 ODT in Major Depressive Disorder

Definium Therapeutics Announces Positive Topline Results from Phase 3 Emerge Study of DT120 Orally Disintegrating Tablet (ODT) in Major Depressive Disorder Definium Therapeutics, Inc. a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes…

Read MoreDefinium Therapeutics Reports Positive Phase 3 Results for DT120 ODT in Major Depressive Disorder